All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
This month, in a Letter to the Editor of the British Journal of Haematology, Alexey V. Danilov from the Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA, and colleagues reported findings of a phase I dose-ranging study of bendamustine and rituximab (BR) in patients with Chronic Lymphocytic Leukemia (CLL) with comorbidities.
Patients were eligible if they had previously untreated (n=5) or Relapsed/Refractory (R/R; n=2) CLL with a Cumulative Illness Rating Scale (CIRS) score of ≥7, one or more grade 3 comorbidities (“severe”), and met International Working Group CLL 2008 criteria for treatment requirement.
A standard 3 + 3 dose escalation design was implemented. Bendamustine was administered at 45mg/m2 on days 1 and 2 of 28 day cycles for up to 6 cycles. Rituximab was administered at 375mg/m2 in cycle 1 and at 500mg/m2 in cycles 2–6). Dose escalation to 70mg/m2, or de-escalation to 25mg/m2 if Dose-Limiting Toxicities (DLT) occurred, was planned for bendamustine.
The primary outcome measures included treatment-related toxicity and identification of the Maximum Tolerated Dose (MTD), defined as the dose cohort above which ≥2/6 patients experienced DLTs. Seven patients were treated in the phase I portion of the study. The dose escalation phase was completed and one patients was enrolled in the expansion cohort; however, slow accrual caused this study to be closed at this point. This Letter to the Editor included results from the dose escalation portion of the study.
The authors stated that their phase I study identified BR at 45mg/m2 at the MTD in patients with CLL and significant comorbidities. In most evaluable patients, efficacy was demonstrated despite markedly reduced exposure to bendamustine; patients were exposed to doses around 30% less than those used in solid cancer trials. The group emphasize that their findings indicate that a dose reduction for BR is required in this population; however, larger studies are required to confirm this finding. Lastly, the authors conclude that CIRS presents as a potential tool in guiding choice and/or dose of treatment in CLL patients.
N/A
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox